WallStSmart

Becton Dickinson and Company (BDX)vsBionano Genomics Inc (BNGO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 77244% more annual revenue ($22.23B vs $28.74M). BDX leads profitability with a 5.1% profit margin vs -109.9%. BDX earns a higher WallStSmart Score of 65/100 (B-).

BDX

Strong Buy

65

out of 100

Grade: B-

Growth: 6.0Profit: 5.0Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.49

BNGO

Avoid

33

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 4/9Altman Z: -13.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+9.9%)

Margin of Safety

+9.9%

Fair Value

$200.45

Current Price

$151.16

$49.29 discount

UndervaluedFair: $200.45Overvalued

Intrinsic value data unavailable for BNGO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX2 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

BNGO1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Areas to Watch

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
25.2x4/10

Moderate valuation

Return on EquityProfitability
4.7%3/10

ROE of 4.7% — below average capital efficiency

Profit MarginProfitability
5.1%3/10

5.1% margin — thin

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

BNGO4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.46M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-84.3%2/10

ROE of -84.3% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bull Case : BNGO

The strongest argument for BNGO centers on Price/Book.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin.

Bear Case : BNGO

The primary concerns for BNGO are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BDX profiles as a value stock while BNGO is a turnaround play — different risk/reward profiles.

BNGO carries more volatility with a beta of 1.62 — expect wider price swings.

BDX is growing revenue faster at 5.2% — sustainability is the question.

BDX generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

BDX scores higher overall (65/100 vs 33/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Bionano Genomics Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Bionano Genomics, Inc. is a life science instrumentation company in the genome analysis space. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?